US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at the 5th China International Import Expo (CIIE). The collaboration is focused on enhancing the management of cardiovascular and cerebrovascular diseases, particularly atrial fibrillation. The two companies will integrate their product and resource advantages to bolster full-process services for patients with atrial fibrillation.
Atrial Fibrillation in China
According to the latest data, there are nearly 20 million patients with atrial fibrillation in China, accounting for about one-fifth of the global total. The stroke risk for patients with atrial fibrillation is 20% to 30%, five times higher than that of the general population. Compared with strokes caused by other reasons, strokes resulting from atrial fibrillation are characterized by higher disability rates, higher fatality rates, and higher recurrence rates. This underscores the critical need for improved management and treatment options for this condition.-Fineline Info & Tech
